Product Launch: Page 4

Veracyte licenses NanoString diagnostic platform in $50M deal

Per the deal, NanoString is due another $10 million as Veracyte's tests are launched on the platform commercially. NanoString's platform enables the simultaneous analysis of RNA, DNA, or protein targets for up to 800 genes.

December 3, 2019

Cancer tests dominate AMP 2019 | FDA renews warning on biotin interference | Cervical cancer testing at home

Dear LabPulse Member,

November 11, 2019

Lexent Bio partners on NGS with Illumina

Confera Dx is designed to monitor treatment response and the level of minimal residual disease (MRD) in cancer patients. The company plans to launch the product as a laboratory-developed test (LDT) with testing done at its own CLIA lab, and Lexent will also pursue clearance by the U.S. Food and Drug Administration (FDA) to enable use in the local labs of hospitals and health systems.

November 7, 2019

Siemens overcomes lagging Diagnostics numbers in Q4

For the period, Siemens Healthineers posted fourth-quarter revenue of $4.615 billion, up 8% after adjusting for currency changes from $4.127 billion in the corresponding quarter of 2018. Net income for the most recent quarter was $565 million, compared with net income of $417 million in the fourth quarter of fiscal 2018.

November 3, 2019

AACC preview: A rough guide to diagnostics on show

Some of the many developments we'll be looking for are described below.

August 1, 2019

Premier Medical launches Patia's diabetes genetic test

The test was developed by Patia, which is based in San Sebastián, Spain, and had already been launched in Europe and Mexico. According to Patia, the test was developed based on studies of 110,000 people with and without diabetes. In addition to the risk score, the product includes a customized report advising lifestyle modifications that can be made in light of the genetic results to track adherence with preventive plans.

July 31, 2019

Kalorama's notable product launches for clinical labs in Q1 2019

In the POC segment, one of the breakthrough approvals from the U.S. Food and Drug Administration (FDA) was for the Sangia total prostate-specific antigen (PSA) test by Opko Health (Woburn, MA) in January. The Sangia test is the first POC test that quantitatively measures total PSA in capillary whole blood, and it is approved for use with the digital rectal exam (DRE) to screen for prostate cancer in men 50 years and older. The test can be administered with a finger prick and results are generated in 12 minutes.

April 24, 2019

Previous Page

Page 4 of 4